Ignite Creation Date:
2025-12-24 @ 11:14 PM
Ignite Modification Date:
2026-01-01 @ 9:07 AM
Study NCT ID:
NCT00689156
Status:
COMPLETED
Last Update Posted:
2018-04-05
First Post:
2008-05-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Epirubicin or Not in Patients With TOP2A (Topoisomerase (DNA) II Alpha (170kD)) Normal Early Breast Cancer
Sponsor:
Danish Breast Cancer Cooperative Group
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
DBCG 07-READ
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None